{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:35:37Z","timestamp":1792784137012,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"2024 Annual Hospital-Level Talent Special Fund of the Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine","award":["FSRC20242D01"],"award-info":[{"award-number":["FSRC20242D01"]}]},{"name":"Heilongjiang Province \u201cOutstanding Young Teachers Basic Research Support Program\u201d Project","award":["YQJH2023150"],"award-info":[{"award-number":["YQJH2023150"]}]},{"name":"Scientific Research Project of Heilongjiang University of Chinese Medicine","award":["2019JC01"],"award-info":[{"award-number":["2019JC01"]}],"id":[{"id":"https:\/\/ror.org\/05x1ptx12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12012-026-10131-w","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:04:42Z","timestamp":1779329082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Inhibitor\u2013Associated Cardiovascular Toxicity: Mechanisms, Clinical Manifestations, and Clinical Impact"],"prefix":"10.1007","volume":"26","author":[{"given":"Zhengyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"11","key":"10131_CR1","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","volume":"128","author":"AH Baik","year":"2021","unstructured":"Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J. E., Tsai, K. K., et al. (2021). Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res, 128(11), 1780\u20131801.","journal-title":"Circ Res"},{"issue":"2","key":"10131_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","volume":"4","author":"J Dine","year":"2017","unstructured":"Dine, J., Gordon, R., Shames, Y., Kasler, M. K., & Barton-Burke, M. (2017). Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer. Asia Pac J Oncol Nurs, 4(2), 127\u2013135.","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"12","key":"10131_CR3","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., et al. (2018). Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. The Lancet Oncology, 19(12), 1579\u20131589.","journal-title":"The Lancet Oncology"},{"issue":"6","key":"10131_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille, C., Ederhy, S., Sassier, M., Cautela, J., Thuny, F., Cohen, A. A., et al. (2020). Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol, 6(6), 865\u2013871.","journal-title":"JAMA Oncol"},{"key":"10131_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R., & Engleman, E. G. (2021). Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review Of Pathology: Mechanisms Of Disease, 16, 223\u2013249.","journal-title":"Annual Review Of Pathology: Mechanisms Of Disease"},{"issue":"1","key":"10131_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11684-019-0735-3","volume":"15","author":"Y Fan","year":"2021","unstructured":"Fan, Y., Geng, Y., Shen, L., & Zhang, Z. (2021). Advances on immune-related adverse events associated with immune checkpoint inhibitors. Front Med, 15(1), 33\u201342.","journal-title":"Front Med"},{"issue":"3","key":"10131_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., et al. (2020). NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal Of The National Comprehensive Cancer Network, 18(3), 230\u2013241.","journal-title":"Journal Of The National Comprehensive Cancer Network"},{"issue":"2","key":"10131_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","volume":"71","author":"N Okiyama","year":"2022","unstructured":"Okiyama, N., & Tanaka, R. (2022). Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergology International : Official Journal Of The Japanese Society Of Allergology, 71(2), 169\u2013178.","journal-title":"Allergology International : Official Journal Of The Japanese Society Of Allergology"},{"issue":"1","key":"10131_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O. 3rd, Brogdon, C., Dadu, R., et al. (2017). Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal For Immunotherapy Of Cancer, 5(1), 95.","journal-title":"Journal For Immunotherapy Of Cancer"},{"issue":"12","key":"10131_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y., Salem, J. E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., et al. (2018). Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol, 4(12), 1721\u20131728.","journal-title":"JAMA Oncol"},{"issue":"5","key":"10131_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu, J. R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., et al. (2019). Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res, 115(5), 854\u2013868.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10131_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"Rubio-Infante, N., Ram\u00edrez-Flores, Y. A., Castillo, E. C., Lozano, O., Garc\u00eda-Rivas, G., & Torre-Amione, G. (2021). Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. European Journal Of Heart Failure, 23(10), 1739\u20131747.","journal-title":"European Journal Of Heart Failure"},{"issue":"3","key":"10131_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/2159-8290.CD-21-0091","volume":"11","author":"A Young","year":"2021","unstructured":"Young, A., & Bluestone, J. A. (2021). At the Heart of Immune Checkpoint Inhibitor-Induced Immune Toxicity. Cancer Discovery, 11(3), 537\u2013539.","journal-title":"Cancer Discovery"},{"issue":"48","key":"10131_CR14","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","volume":"42","author":"C Dolladille","year":"2021","unstructured":"Dolladille, C., Akroun, J., Morice, P. M., Dompmartin, A., Ezine, E., Sassier, M., et al. (2021). Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. European Heart Journal, 42(48), 4964\u20134977.","journal-title":"European Heart Journal"},{"issue":"16","key":"10131_CR15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","volume":"42","author":"M D\u2019Souza","year":"2021","unstructured":"D\u2019Souza, M., Nielsen, D., Svane, I. M., Iversen, K., Rasmussen, P. V., Madelaire, C., et al. (2021). The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. European Heart Journal, 42(16), 1621\u20131631.","journal-title":"European Heart Journal"},{"issue":"5","key":"10131_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder, A., Chen, Y., Procureur, A., Gradone, A., Azam, T. U., Perry, D., et al. (2022). Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis. JACC CardioOncol, 4(5), 689\u2013700.","journal-title":"JACC CardioOncol"},{"issue":"8","key":"10131_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/heartjnl-2019-315852","volume":"106","author":"M Imazio","year":"2020","unstructured":"Imazio, M., Colopi, M., & De Ferrari, G. M. (2020). Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes. Heart, 106(8), 569\u2013574.","journal-title":"Heart"},{"issue":"7","key":"10131_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","volume":"41","author":"V Jain","year":"2018","unstructured":"Jain, V., Mohebtash, M., Rodrigo, M. E., Ruiz, G., Atkins, M. B., & Barac, A. (2018). Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. Journal Of Immunotherapy, 41(7), 332\u2013335.","journal-title":"Journal Of Immunotherapy"},{"key":"10131_CR19","doi-asserted-by":"crossref","unstructured":"Gong, J., Drobni, Z. D., Zafar, A., Quinaglia, T., Hartmann, S., Gilman, H. K. (2021). Pericardial disease in patients treated with immune checkpoint inhibitors. Journal For Immunotherapy Of Cancer. ;9(6).","DOI":"10.1136\/jitc-2021-002771"},{"issue":"1","key":"10131_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12916-024-03261-x","volume":"22","author":"B Gong","year":"2024","unstructured":"Gong, B., Guo, Y., Li, Y., Wang, J., Zhou, G., Chen, Y. H., et al. (2024). Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium. Bmc Medicine, 22(1), 44.","journal-title":"Bmc Medicine"},{"issue":"1","key":"10131_CR21","first-page":"10","volume":"7","author":"N Waheed","year":"2021","unstructured":"Waheed, N., Fradley, M. G., DeRemer, D. L., Mahmoud, A., Shah, C. P., Langaee, T. Y., et al. (2021). Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardiooncology, 7(1), 10.","journal-title":"Cardiooncology"},{"issue":"5","key":"10131_CR22","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam, A., & Prasad, V. (2019). Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open, 2(5), e192535.","journal-title":"JAMA Netw Open"},{"key":"10131_CR23","doi-asserted-by":"publisher","first-page":"1340373","DOI":"10.3389\/fimmu.2024.1340373","volume":"15","author":"W Jo","year":"2024","unstructured":"Jo, W., Won, T., Daoud, A., & \u010cih\u00e1kov\u00e1, D. (2024). Immune checkpoint inhibitors associated cardiovascular immune-related adverse events. Frontiers In Immunology, 15, 1340373.","journal-title":"Frontiers In Immunology"},{"issue":"1","key":"10131_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","volume":"3","author":"L Zhang","year":"2021","unstructured":"Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N., & Neilan, T. G. (2021). The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol, 3(1), 35\u201347.","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10131_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.19.01381","volume":"38","author":"AA Tarhini","year":"2020","unstructured":"Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., et al. (2020). Phase III Study of Adjuvant Ipilimumab (3 or 10\u00a0mg\/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. Journal Of Clinical Oncology, 38(6), 567\u2013575.","journal-title":"Journal Of Clinical Oncology"},{"issue":"4","key":"10131_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022). Immune-checkpoint inhibitors: long-term implications of toxicity. Nature Reviews. Clinical Oncology, 19(4), 254\u2013267.","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"16","key":"10131_CR27","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., et al. (2018). Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal Of The American College Of Cardiology, 71(16), 1755\u20131764.","journal-title":"Journal Of The American College Of Cardiology"},{"issue":"12","key":"10131_CR28","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., et al. (2015). Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals Of Oncology, 26(12), 2375\u20132391.","journal-title":"Annals Of Oncology"},{"issue":"8","key":"10131_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41568-024-00715-5","volume":"24","author":"AZ Munir","year":"2024","unstructured":"Munir, A. Z., Gutierrez, A., Qin, J., Lichtman, A. H., & Moslehi, J. J. (2024). Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart. Nature Reviews Cancer, 24(8), 540\u2013553.","journal-title":"Nature Reviews Cancer"},{"key":"10131_CR30","doi-asserted-by":"publisher","first-page":"786046","DOI":"10.3389\/fimmu.2021.786046","volume":"12","author":"SK Wong","year":"2021","unstructured":"Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021). Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. Frontiers In Immunology, 12, 786046.","journal-title":"Frontiers In Immunology"},{"key":"10131_CR31","doi-asserted-by":"crossref","unstructured":"Noseda, R., Ruinelli, L., Gaag, L. C. V., & Ceschi, A. (2020). Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study. Cancers (Basel). ;12(11).","DOI":"10.3390\/cancers12113480"},{"key":"10131_CR32","doi-asserted-by":"crossref","unstructured":"Varga, Z., Gergely, T. G., Drobni, Z. D., Kovacs, T., Sayour, N. V., Toth, V. E. (2024). Prior cardiac ischemic injury exacerbates immune checkpoint inhibitor-induced cardiotoxicity. Cardiovascular Research. ;120(Supplement_1).","DOI":"10.1093\/cvr\/cvae088.091"},{"key":"10131_CR33","doi-asserted-by":"publisher","first-page":"726426","DOI":"10.3389\/fcvm.2021.726426","volume":"8","author":"DL Mocan-Hognogi","year":"2021","unstructured":"Mocan-Hognogi, D. L., Tranc\u01ce, S., Farca\u015f, A. D., Mocan-Hognogi, R. F., P\u00e2rvu, A. V., & Bojan, A. S. (2021). Immune Checkpoint Inhibitors and the Heart. Front Cardiovasc Med, 8, 726426.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10131_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","volume":"46","author":"E Raschi","year":"2023","unstructured":"Raschi, E., Rossi, S., De Giglio, A., Fusaroli, M., Burgazzi, F., Rinaldi, R., et al. (2023). Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. Drug Safety, 46(9), 819\u2013833.","journal-title":"Drug Safety"},{"issue":"42","key":"10131_CR35","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","volume":"43","author":"F Thuny","year":"2022","unstructured":"Thuny, F., Naidoo, J., & Neilan, T. G. (2022). Cardiovascular complications of immune checkpoint inhibitors for cancer. European Heart Journal, 43(42), 4458\u20134468.","journal-title":"European Heart Journal"},{"key":"10131_CR36","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.2147\/JIR.S311616","volume":"14","author":"W Zou","year":"2021","unstructured":"Zou, W., Lu, J., & Hao, Y. (2021). Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. J Inflamm Res, 14, 3077\u20133088.","journal-title":"J Inflamm Res"},{"key":"10131_CR37","doi-asserted-by":"crossref","unstructured":"Dolladille, C., Ederhy, S., Allouche, S., Dupas, Q., Gervais, R., Madelaine, J. (2020). Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. Journal For Immunotherapy Of Cancer. ;8(1).","DOI":"10.1136\/jitc-2019-000261"},{"issue":"10","key":"10131_CR38","doi-asserted-by":"publisher","first-page":"e7233","DOI":"10.1002\/cam4.7233","volume":"13","author":"Y Zheng","year":"2024","unstructured":"Zheng, Y., Chen, Z., Song, W., Xu, Y., Zhao, Z., Sun, Y., et al. (2024). Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study. Cancer Medicine, 13(10), e7233.","journal-title":"Cancer Medicine"},{"issue":"3","key":"10131_CR39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaccao.2021.06.007","volume":"3","author":"C Bergom","year":"2021","unstructured":"Bergom, C., Bradley, J. A., Ng, A. K., Samson, P., Robinson, C., Lopez-Mattei, J., et al. (2021). Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification. JACC CardioOncol, 3(3), 343\u2013359.","journal-title":"JACC CardioOncol"},{"issue":"18","key":"10131_CR40","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., et al. (2016). Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal Of Medicine, 375(18), 1749\u20131755.","journal-title":"New England Journal Of Medicine"},{"issue":"3","key":"10131_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/cvr\/cvx248","volume":"114","author":"PJH Kusters","year":"2018","unstructured":"Kusters, P. J. H., Lutgens, E., & Seijkens, T. T. P. (2018). Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. Cardiovasc Res, 114(3), 368\u2013377.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10131_CR42","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019). Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends In Immunology, 40(6), 511\u2013523.","journal-title":"Trends In Immunology"},{"issue":"7","key":"10131_CR43","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang, S. J., Dougan, S. K., & Dougan, M. (2023). Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer, 9(7), 543\u2013553.","journal-title":"Trends Cancer"},{"issue":"17","key":"10131_CR44","doi-asserted-by":"publisher","first-page":"e37278","DOI":"10.1016\/j.heliyon.2024.e37278","volume":"10","author":"ML Zhao","year":"2024","unstructured":"Zhao, M. L., Liang, C., Jiang, W. W., Zhang, M., Guan, H., Hong, Z., et al. (2024). Inhibition of CTLA-4 accelerates atherosclerosis in hyperlipidemic mice by modulating the Th1\/Th2 balance via the NF-\u03baB signaling pathway. Heliyon, 10(17), e37278.","journal-title":"Heliyon"},{"issue":"21","key":"10131_CR45","doi-asserted-by":"publisher","first-page":"E4223","DOI":"10.1073\/pnas.1617941114","volume":"114","author":"UA Ramagopal","year":"2017","unstructured":"Ramagopal, U. A., Liu, W., Garrett-Thomson, S. C., Bonanno, J. B., Yan, Q., Srinivasan, M., et al. (2017). Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc Natl Acad Sci U S A, 114(21), E4223\u2013e32.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10131_CR46","doi-asserted-by":"publisher","first-page":"1561968","DOI":"10.3389\/fimmu.2025.1561968","volume":"16","author":"S Huang","year":"2025","unstructured":"Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025). The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure. Frontiers In Immunology, 16, 1561968.","journal-title":"Frontiers In Immunology"},{"issue":"5899","key":"10131_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., et al. (2008). CTLA-4 control over Foxp3\u2009+\u2009regulatory T cell function. Science, 322(5899), 271\u2013275.","journal-title":"Science"},{"issue":"12","key":"10131_CR48","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.autrev.2013.07.002","volume":"12","author":"J Romo-Tena","year":"2013","unstructured":"Romo-Tena, J., G\u00f3mez-Mart\u00edn, D., & Alcocer-Varela, J. (2013). CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev, 12(12), 1171\u20131176.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10131_CR49","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5858\/arpa.2016-0361-RA","volume":"141","author":"J Guan","year":"2017","unstructured":"Guan, J., Lim, K. S., Mekhail, T., & Chang, C. C. (2017). Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)\/PD-L1 Blockade: A Key Player Against Various Cancers. Archives Of Pathology And Laboratory Medicine, 141(6), 851\u2013861.","journal-title":"Archives Of Pathology And Laboratory Medicine"},{"issue":"5502","key":"10131_CR50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 291(5502), 319\u2013322.","journal-title":"Science"},{"issue":"8","key":"10131_CR51","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1161\/HYPERTENSIONAHA.123.22393","volume":"81","author":"L Wang","year":"2024","unstructured":"Wang, L., Mu, M., Guo, Y., Huang, J., Zhang, R., Zhang, M., et al. (2024). PD-1\/PD-L1 Provides Protective Role in Hypoxia-Induced Pulmonary Vascular Remodeling. Hypertension, 81(8), 1822\u20131836.","journal-title":"Hypertension"},{"issue":"3","key":"10131_CR52","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","volume":"101","author":"VA Love","year":"2007","unstructured":"Love, V. A., Grabie, N., Duramad, P., Stavrakis, G., Sharpe, A., & Lichtman, A. (2007). CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res, 101(3), 248\u2013257.","journal-title":"Circ Res"},{"issue":"6","key":"10131_CR53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","volume":"36","author":"T Matsumoto","year":"2016","unstructured":"Matsumoto, T., Sasaki, N., Yamashita, T., Emoto, T., Kasahara, K., Mizoguchi, T., et al. (2016). Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, And Vascular Biology, 36(6), 1141\u20131151.","journal-title":"Arteriosclerosis, Thrombosis, And Vascular Biology"},{"issue":"6","key":"10131_CR54","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","volume":"79","author":"JT Vuong","year":"2022","unstructured":"Vuong, J. T., Stein-Merlob, A. F., Nayeri, A., Sallam, T., Neilan, T. G., & Yang, E. H. (2022). Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review. Journal Of The American College Of Cardiology, 79(6), 577\u2013593.","journal-title":"Journal Of The American College Of Cardiology"},{"issue":"5","key":"10131_CR55","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/cvr\/cvz025","volume":"115","author":"N Grabie","year":"2019","unstructured":"Grabie, N., Lichtman, A. H., & Padera, R. (2019). T cell checkpoint regulators in the heart. Cardiovasc Res, 115(5), 869\u2013877.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10131_CR56","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41569-021-00578-5","volume":"18","author":"I Fern\u00e1ndez-Ruiz","year":"2021","unstructured":"Fern\u00e1ndez-Ruiz, I. (2021). CD200 is an atheroprotective immune checkpoint. Nature Reviews. Cardiology, 18(7), 461.","journal-title":"Nature Reviews. Cardiology"},{"issue":"1","key":"10131_CR57","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1160\/TH16-04-0318","volume":"117","author":"H Winkels","year":"2017","unstructured":"Winkels, H., Meiler, S., Smeets, E., Lievens, D., Engel, D., Spitz, C., et al. (2017). CD70 limits atherosclerosis and promotes macrophage function. Thrombosis And Haemostasis, 117(1), 164\u2013175.","journal-title":"Thrombosis And Haemostasis"},{"issue":"48","key":"10131_CR58","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1093\/eurheartj\/ehx517","volume":"38","author":"H Winkels","year":"2017","unstructured":"Winkels, H., Meiler, S., Lievens, D., Engel, D., Spitz, C., B\u00fcrger, C., et al. (2017). CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice. European Heart Journal, 38(48), 3590\u20133599.","journal-title":"European Heart Journal"},{"issue":"10","key":"10131_CR59","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio, M. L., Grabie, N., Bu, D. X., Sharpe, A. H., & Lichtman, A. H. (2012). PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. The Journal Of Immunology, 188(10), 4876\u20134884.","journal-title":"The Journal Of Immunology"},{"issue":"11","key":"10131_CR60","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.it.2025.07.012","volume":"46","author":"J Rossjohn","year":"2025","unstructured":"Rossjohn, J., Nezi, L., Walz, J. S., Tagliamonte, M., & Buonaguro, L. (2025). Molecular mimicry as a driver of T cell-mediated tumour immunity. Trends In Immunology, 46(11), 741\u2013752.","journal-title":"Trends In Immunology"},{"issue":"8041","key":"10131_CR61","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","volume":"636","author":"SM Blum","year":"2024","unstructured":"Blum, S. M., Zlotoff, D. A., Smith, N. P., Kernin, I. J., Ramesh, S., Zubiri, L., et al. (2024). Immune responses in checkpoint myocarditis across heart, blood and tumour. Nature, 636(8041), 215\u2013223.","journal-title":"Nature"},{"key":"10131_CR62","doi-asserted-by":"publisher","first-page":"e075859","DOI":"10.1136\/bmj-2023-075859","volume":"385","author":"NL Palaskas","year":"2024","unstructured":"Palaskas, N. L., Ali, H. J., Koutroumpakis, E., Ganatra, S., & Deswal, A. (2024). Cardiovascular toxicity of immune therapies for cancer. Bmj, 385, e075859.","journal-title":"Bmj"},{"issue":"1","key":"10131_CR63","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","volume":"13","author":"ST Kim","year":"2022","unstructured":"Kim, S. T., Chu, Y., Misoi, M., Suarez-Almazor, M. E., Tayar, J. H., Lu, H., et al. (2022). Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 13(1), 1970.","journal-title":"Nature Communications"},{"issue":"1","key":"10131_CR64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","volume":"41","author":"Y Liu","year":"2020","unstructured":"Liu, Y., & Zheng, P. (2020). Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy. Trends In Pharmacological Sciences, 41(1), 4\u201312.","journal-title":"Trends In Pharmacological Sciences"},{"issue":"7937","key":"10131_CR65","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod, M. L., Meijers, W. C., Screever, E. M., Qin, J., Carroll, M. G., Sun, X., et al. (2022). T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature, 611(7937), 818\u2013826.","journal-title":"Nature"},{"issue":"5","key":"10131_CR66","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/ATVBAHA.123.320409","volume":"44","author":"S Takeda","year":"2024","unstructured":"Takeda, S., Emoto, T., Yamashita, T., Yamamoto, H., Takaya, T., Sawada, T., et al. (2024). Single-Cell RNA Sequencing Reveals an Immune Landscape of CD4(+) T Cells in Coronary Culprit Plaques With Acute Coronary Syndrome in Humans-Brief Report. Arteriosclerosis, Thrombosis, And Vascular Biology, 44(5), 1135\u20131143.","journal-title":"Arteriosclerosis, Thrombosis, And Vascular Biology"},{"key":"10131_CR67","doi-asserted-by":"crossref","unstructured":"Hinkley, H., Counts, D. A., VonCanon, E., & Lacy, M. (2023). T Cells in Atherosclerosis: Key Players in the Pathogenesis of Vascular Disease. Cells. ;12(17).","DOI":"10.3390\/cells12172152"},{"key":"10131_CR68","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.3389\/fimmu.2019.03046","volume":"10","author":"C Tay","year":"2019","unstructured":"Tay, C., Kanellakis, P., Hosseini, H., Cao, A., Toh, B. H., Bobik, A., et al. (2019). B Cell and CD4 T Cell Interactions Promote Development of Atherosclerosis. Frontiers In Immunology, 10, 3046.","journal-title":"Frontiers In Immunology"},{"issue":"2","key":"10131_CR69","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999). Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 11(2), 141\u2013151.","journal-title":"Immunity"},{"issue":"7","key":"10131_CR70","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.3324\/haematol.2017.185777","volume":"103","author":"N Martinez-Calle","year":"2018","unstructured":"Martinez-Calle, N., Rodriguez-Otero, P., Villar, S., Mej\u00edas, L., Melero, I., Prosper, F., et al. (2018). Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica, 103(7), e318\u2013e21.","journal-title":"Haematologica"},{"issue":"14\u201315","key":"10131_CR71","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.molimm.2003.11.007","volume":"40","author":"K Fa\u00e9","year":"2004","unstructured":"Fa\u00e9, K., Kalil, J., Toubert, A., & Guilherme, L. (2004). Heart infiltrating T cell clones from a rheumatic heart disease patient display a common TCR usage and a degenerate antigen recognition pattern. Molecular Immunology, 40(14\u201315), 1129\u20131135.","journal-title":"Molecular Immunology"},{"key":"10131_CR72","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ics.2005.11.073","volume":"1289","author":"K Fa\u00e9","year":"2006","unstructured":"Fa\u00e9, K., Oshiro, S. E., Tanaka, A. C., Pomerantzeff, P. M. A., Kalil, J., & Guilherme, L. (2006). T cell molecular mimicry and rheumatic heart disease. International Congress Series, 1289, 293\u2013295.","journal-title":"International Congress Series"},{"key":"10131_CR73","doi-asserted-by":"crossref","unstructured":"Cunningham, M. W. (2019). Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae. Microbiol Spectr. ;7(4).","DOI":"10.1128\/microbiolspec.GPP3-0045-2018"},{"issue":"10\u201311","key":"10131_CR74","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00011-022-01611-0","volume":"71","author":"W He","year":"2022","unstructured":"He, W., Chen, P., Chen, Q., Cai, Z., & Zhang, P. (2022). Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction. Inflammation Research, 71(10\u201311), 1143\u20131158.","journal-title":"Inflammation Research"},{"key":"10131_CR75","doi-asserted-by":"crossref","unstructured":"Wang, X., Guo, Z., Ding, Z., & Mehta, J. L. (2018). Inflammation, Autophagy, and Apoptosis After Myocardial Infarction. J Am Heart Assoc. ;7(9).","DOI":"10.1161\/JAHA.117.008024"},{"key":"10131_CR76","doi-asserted-by":"publisher","first-page":"6401341","DOI":"10.1155\/2020\/6401341","volume":"2020","author":"PC Bradshaw","year":"2020","unstructured":"Bradshaw, P. C., Seeds, W. A., Miller, A. C., Mahajan, V. R., & Curtis, W. M. (2020). COVID-19: Proposing a Ketone-Based Metabolic Therapy as a Treatment to Blunt the Cytokine Storm. Oxid Med Cell Longev, 2020, 6401341.","journal-title":"Oxid Med Cell Longev"},{"issue":"16","key":"10131_CR77","doi-asserted-by":"publisher","first-page":"e021428","DOI":"10.1161\/JAHA.121.021428","volume":"10","author":"JC Chang","year":"2021","unstructured":"Chang, J. C., Matsubara, D., Morgan, R. W., Diorio, C., Nadaraj, S., Teachey, D. T., et al. (2021). Skewed Cytokine Responses Rather Than the Magnitude of the Cytokine Storm May Drive Cardiac Dysfunction in Multisystem Inflammatory Syndrome in Children. J Am Heart Assoc, 10(16), e021428.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10131_CR78","doi-asserted-by":"publisher","first-page":"2372875","DOI":"10.1080\/2162402X.2024.2372875","volume":"13","author":"O Hamida","year":"2024","unstructured":"Hamida, O., Karlsson, F., Lundqvist, A., Gerling, M., & Liu, L. L. (2024). Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden. Oncoimmunology, 13(1), 2372875.","journal-title":"Oncoimmunology"},{"key":"10131_CR79","doi-asserted-by":"crossref","unstructured":"Ma, P., Liu, J., Qin, J., Lai, L., Heo, G. S., Luehmann, H. (2023). Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis. bioRxiv.","DOI":"10.1101\/2023.04.28.538426"},{"issue":"2","key":"10131_CR80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41569-022-00821-7","volume":"20","author":"I Fern\u00e1ndez-Ruiz","year":"2023","unstructured":"Fern\u00e1ndez-Ruiz, I. (2023). \u03b1-Myosin-specific CD8(+) T cells drive ICI-related myocarditis. Nature Reviews. Cardiology, 20(2), 75.","journal-title":"Nature Reviews. Cardiology"},{"issue":"1","key":"10131_CR81","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","volume":"33","author":"SN Champion","year":"2020","unstructured":"Champion, S. N., & Stone, J. R. (2020). Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Modern Pathology, 33(1), 99\u2013108.","journal-title":"Modern Pathology"},{"issue":"1","key":"10131_CR82","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.123.067189","volume":"149","author":"DT \u010cih\u00e1kov\u00e1","year":"2024","unstructured":"\u010cih\u00e1kov\u00e1, D. T. (2024). Cells and Macrophages Drive Pathogenesis of Immune Checkpoint Inhibitor Myocarditis. Circulation, 149(1), 67\u201369.","journal-title":"Circulation"},{"issue":"1","key":"10131_CR83","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","volume":"149","author":"P Ma","year":"2024","unstructured":"Ma, P., Liu, J., Qin, J., Lai, L., Heo, G. S., Luehmann, H., et al. (2024). Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis. Circulation, 149(1), 48\u201366.","journal-title":"Circulation"},{"key":"10131_CR84","doi-asserted-by":"crossref","unstructured":"Ali, A., Caldwell, R., Pina, G., Beinart, N., Jensen, G., Yusuf, S. W. (2024). Elevated IL-6 and Tumor Necrosis Factor-\u03b1 in Immune Checkpoint Inhibitor Myocarditis. Diseases. ;12(5).","DOI":"10.3390\/diseases12050088"},{"issue":"5","key":"10131_CR85","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCRESAHA.124.325652","volume":"136","author":"YV Huang","year":"2025","unstructured":"Huang, Y. V., Sun, Y., Chou, H., Wagner, N., Vitale, M. R., Bayer, A. L., et al. (2025). Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis. Circ Res, 136(5), 473\u2013490.","journal-title":"Circ Res"},{"key":"10131_CR86","doi-asserted-by":"crossref","unstructured":"Sun, J., Wu, W., Wang, Y., Zhang, J., Qiu, S., Guan, Z. (2025). MLKL-Mediated Necroptosis Predominantly Contributes to Immune-Associated Myocardial Damage. Inflammation.","DOI":"10.1007\/s10753-025-02298-1"},{"key":"10131_CR87","doi-asserted-by":"publisher","first-page":"1161243","DOI":"10.3389\/fphar.2023.1161243","volume":"14","author":"Y Wu","year":"2023","unstructured":"Wu, Y., Xu, Y., & Xu, L. (2023). Drug therapy for myocarditis induced by immune checkpoint inhibitors. Frontiers In Pharmacology, 14, 1161243.","journal-title":"Frontiers In Pharmacology"},{"issue":"1","key":"10131_CR88","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","volume":"15","author":"SJ Sun","year":"2024","unstructured":"Sun, S. J., Jiao, X. D., Chen, Z. G., Cao, Q., Zhu, J. H., Shen, Q. R., et al. (2024). Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation. Nature Communications, 15(1), 6640.","journal-title":"Nature Communications"},{"issue":"669","key":"10131_CR89","doi-asserted-by":"publisher","first-page":"eade4035","DOI":"10.1126\/scitranslmed.ade4035","volume":"14","author":"PK Nguyen","year":"2022","unstructured":"Nguyen, P. K., & Wu, S. M. (2022). Sex differences in ICI myocarditis: Hormones to the rescue. Science Translational Medicine, 14(669), eade4035.","journal-title":"Science Translational Medicine"},{"issue":"7","key":"10131_CR90","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-023-00986-9","volume":"21","author":"TG Gergely","year":"2024","unstructured":"Gergely, T. G., Drobni, Z. D., Kallikourdis, M., Zhu, H., Meijers, W. C., Neilan, T. G., et al. (2024). Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure. Nature Reviews. Cardiology, 21(7), 443\u2013462.","journal-title":"Nature Reviews. Cardiology"},{"key":"10131_CR91","doi-asserted-by":"crossref","unstructured":"Dimitroglou, Y., Aggeli, C., Theofilis, P., Tsioufis, P., Oikonomou, E., Chasikidis, C. (2023). Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes. Life (Basel). ;13(8).","DOI":"10.3390\/life13081669"},{"issue":"2","key":"10131_CR92","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamacardio.2023.4820","volume":"9","author":"RB Thorolfsdottir","year":"2024","unstructured":"Thorolfsdottir, R. B., Jonsdottir, A. B., Sveinbjornsson, G., Aegisdottir, H. M., Oddsson, A., Stefansson, O. A., et al. (2024). Variants at the Interleukin 1 Gene Locus and Pericarditis. JAMA Cardiol, 9(2), 165\u2013172.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10131_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11886-021-01621-0","volume":"24","author":"TKM Wang","year":"2022","unstructured":"Wang, T. K. M., & Klein, A. L. (2022). Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis. Current Cardiology Reports, 24(1), 23\u201330.","journal-title":"Current Cardiology Reports"},{"key":"10131_CR94","doi-asserted-by":"crossref","unstructured":"Vlachakis, P. K., Theofilis, P., Kachrimanidis, I., Giannakopoulos, K., Drakopoulou, M., Apostolos, A. (2024). The Role of Inflammasomes in Heart Failure. International Journal Of Molecular Sciences. ;25(10).","DOI":"10.3390\/ijms25105372"},{"key":"10131_CR95","doi-asserted-by":"crossref","unstructured":"Theofilis, P., Oikonomou, E., Chasikidis, C., Tsioufis, K., & Tousoulis, D. (2023). Inflammasomes in Atherosclerosis-From Pathophysiology to Treatment. Pharmaceuticals (Basel). ;16(9).","DOI":"10.3390\/ph16091211"},{"issue":"7","key":"10131_CR96","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1007\/s12325-020-01386-y","volume":"37","author":"ML Canale","year":"2020","unstructured":"Canale, M. L., Camerini, A., Casolo, G., Lilli, A., Bisceglia, I., Parrini, I., et al. (2020). Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy. Adv Ther, 37(7), 3178\u20133184.","journal-title":"Adv Ther"},{"issue":"7","key":"10131_CR97","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11886-017-0866-6","volume":"19","author":"B Xu","year":"2017","unstructured":"Xu, B., Harb, S. C., & Cremer, P. C. (2017). New Insights into Pericarditis: Mechanisms of Injury and Therapeutic Targets. Current Cardiology Reports, 19(7), 60.","journal-title":"Current Cardiology Reports"},{"issue":"9","key":"10131_CR98","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4330\/wjc.v10.i9.87","volume":"10","author":"V Ramasamy","year":"2018","unstructured":"Ramasamy, V., Mayosi, B. M., Sturrock, E. D., & Ntsekhe, M. (2018). Established and novel pathophysiological mechanisms of pericardial injury and constrictive pericarditis. World Journal Of Cardiology, 10(9), 87\u201396.","journal-title":"World Journal Of Cardiology"},{"issue":"1","key":"10131_CR99","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s40425-019-0760-4","volume":"7","author":"A Saade","year":"2019","unstructured":"Saade, A., Mansuet-Lupo, A., Arrondeau, J., Thibault, C., Mirabel, M., Goldwasser, F., et al. (2019). Pericardial effusion under nivolumab: case-reports and review of the literature. Journal For Immunotherapy Of Cancer, 7(1), 266.","journal-title":"Journal For Immunotherapy Of Cancer"},{"issue":"5","key":"10131_CR100","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1042\/CS20200331","volume":"135","author":"AH Baik","year":"2021","unstructured":"Baik, A. H., Tsai, K. K., Oh, D. Y., & Aras, M. A. (2021). Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clin Sci (Lond), 135(5), 703\u2013724.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10131_CR101","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00395-024-01068-8","volume":"120","author":"TG Gergely","year":"2025","unstructured":"Gergely, T. G., Drobni, Z. D., Sayour, N. V., Ferdinandy, P., & Varga, Z. V. (2025). Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. Basic Research In Cardiology, 120(1), 187\u2013205.","journal-title":"Basic Research In Cardiology"},{"key":"10131_CR102","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, S., & Zernecke, A. (2020). CD8(+) T Cells in Atherosclerosis. Cells. ;10(1).","DOI":"10.3390\/cells10010037"},{"issue":"1","key":"10131_CR103","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41392-024-01840-1","volume":"9","author":"R Chen","year":"2024","unstructured":"Chen, R., Zhang, H., Tang, B., Luo, Y., Yang, Y., Zhong, X., et al. (2024). Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther, 9(1), 130.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10131_CR104","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1161\/CIRCRESAHA.124.324260","volume":"135","author":"L Lou","year":"2024","unstructured":"Lou, L., Detering, L., Luehmann, H., Amrute, J. M., Sultan, D., Ma, P., et al. (2024). Visualizing Immune Checkpoint Inhibitors Derived Inflammation in Atherosclerosis. Circ Res, 135(10), 990\u20131003.","journal-title":"Circ Res"},{"issue":"1","key":"10131_CR105","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1186\/s40001-025-02994-6","volume":"30","author":"S Wu","year":"2025","unstructured":"Wu, S., Tan, X., & Cheng, G. (2025). SPTBN1 overexpression ameliorates atherosclerosis by inhibiting oxidative stress and inflammation via regulating the TRIM37\/TRAF2\/NF-\u03baB pathway. European Journal Of Medical Research, 30(1), 781.","journal-title":"European Journal Of Medical Research"},{"key":"10131_CR106","doi-asserted-by":"crossref","unstructured":"Poels, K., van Leent, M. M. T., Reiche, M. E., Kusters, P. J. H., Huveneers, S., de Winther, M. P. J. (2020). Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice. Cells. ;9(9).","DOI":"10.3390\/cells9091987"},{"issue":"4","key":"10131_CR107","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","volume":"2","author":"K Poels","year":"2020","unstructured":"Poels, K., van Leent, M. M. T., Boutros, C., Tissot, H., Roy, S., Meerwaldt, A. E., et al. (2020). Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. JACC CardioOncol, 2(4), 599\u2013610.","journal-title":"JACC CardioOncol"},{"key":"10131_CR108","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fimmu.2018.00315","volume":"9","author":"R Hid Cadena","year":"2018","unstructured":"Hid Cadena, R., Abdulahad, W. H., Hospers, G. A. P., Wind, T. T., Boots, A. M. H., Heeringa, P., et al. (2018). Checks and Balances in Autoimmune Vasculitis. Frontiers In Immunology, 9, 315.","journal-title":"Frontiers In Immunology"},{"key":"10131_CR109","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fimmu.2014.00504","volume":"5","author":"LL Lintermans","year":"2014","unstructured":"Lintermans, L. L., Stegeman, C. A., Heeringa, P., & Abdulahad, W. H. (2014). T cells in vascular inflammatory diseases. Frontiers In Immunology, 5, 504.","journal-title":"Frontiers In Immunology"},{"issue":"1","key":"10131_CR110","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.it.2011.09.006","volume":"33","author":"JS Pober","year":"2012","unstructured":"Pober, J. S., & Tellides, G. (2012). Participation of blood vessel cells in human adaptive immune responses. Trends In Immunology, 33(1), 49\u201357.","journal-title":"Trends In Immunology"},{"issue":"3","key":"10131_CR111","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/08916934.2015.1027815","volume":"48","author":"T Shirai","year":"2015","unstructured":"Shirai, T., Hilhorst, M., Harrison, D. G., Goronzy, J. J., & Weyand, C. M. (2015). Macrophages in vascular inflammation\u2013From atherosclerosis to vasculitis. Autoimmunity, 48(3), 139\u2013151.","journal-title":"Autoimmunity"},{"key":"10131_CR112","doi-asserted-by":"publisher","first-page":"587089","DOI":"10.3389\/fimmu.2020.587089","volume":"11","author":"R Watanabe","year":"2020","unstructured":"Watanabe, R., Berry, G. J., Liang, D. H., Goronzy, J. J., & Weyand, C. M. (2020). Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. Frontiers In Immunology, 11, 587089.","journal-title":"Frontiers In Immunology"},{"key":"10131_CR113","doi-asserted-by":"crossref","unstructured":"Hosseini, H., Yi, L., Kanellakis, P., Cao, A., Tay, C., Peter, K. (2018). Anti-TIM-1 Monoclonal Antibody (RMT1-10) Attenuates Atherosclerosis By Expanding IgM-producing B1a Cells. J Am Heart Assoc. ;7(13).","DOI":"10.1161\/JAHA.117.008447"},{"issue":"5","key":"10131_CR114","doi-asserted-by":"publisher","first-page":"H1060","DOI":"10.1152\/ajpheart.00859.2016","volume":"312","author":"P Srikakulapu","year":"2017","unstructured":"Srikakulapu, P., & McNamara, C. A. (2017). B cells and atherosclerosis. American Journal Of Physiology Heart And Circulatory Physiology, 312(5), H1060\u2013h7.","journal-title":"American Journal Of Physiology Heart And Circulatory Physiology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10131-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10131-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10131-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:36:43Z","timestamp":1782848203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10131-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10131"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10131-w","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"55"}}